Literature DB >> 20890963

DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer.

Amy Sharma1, Christoph J Heuck, Melissa J Fazzari, Jayesh Mehta, Seema Singhal, John M Greally, Amit Verma.   

Abstract

Epigenetics refers to heritable modifications of the genome that are not a result of changes in the DNA sequence and result in phenotypic changes. These changes can be stably transmitted through cell division and are potentially reversible. Epigenetic events are very important during normal development wherein a single progenitor cell proliferates and differentiates into various somatic cell types. This process occurs through modification of the genome without changing the genetic code. Because epigenetic control of gene expression is so important, aberrant epigenetic regulation can lead to disease and cancer. This article reviews epigenetic changes seen in cancer by examining epigenetic changes commonly found in multiple myeloma, a common hematologic malignancy of plasma cells. Epigenetic control of gene expression can be exerted by changes in DNA methylation, histone modifications, and expression of noncoding RNAs. Each of these regulatory mechanisms interacts with the others at different genomic locations and can be measured quantitatively within the cell, requiring that we consider these mechanisms not individually but as a biological system. DNA methylation was the earliest discovered epigenetic regulator and has been the focus of most investigations in cancer. We have thus focused on DNA methylation changes in the pathogenesis of multiple myeloma, which promises to become an excellent model for systems biological studies of epigenomic dysregulation in human disease.
© 2010 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890963     DOI: 10.1002/wsbm.89

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Syst Biol Med        ISSN: 1939-005X


  25 in total

1.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

2.  Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.

Authors:  Hongyu Gao; Huihan Wang; Wei Yang
Journal:  Int J Hematol       Date:  2017-03-18       Impact factor: 2.490

3.  Notable roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia.

Authors:  Jing Wang; Luoming Hua; Ming Guo; Lin Yang; Xiaojun Liu; Yanmeng Li; Xiaoyan Shang; Jianmin Luo
Journal:  Oncol Lett       Date:  2017-04-19       Impact factor: 2.967

4.  Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B.

Authors:  Lu Wen; Yan Chen; Ling-lan Zeng; Fei Zhao; Rui Li; Yuan Liu; Chun Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-11-28       Impact factor: 6.150

Review 5.  Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Andrew M Kaz; William M Grady; Matthew D Stachler; Adam J Bass
Journal:  Gastroenterol Clin North Am       Date:  2015-04-01       Impact factor: 3.806

Review 6.  Metabolism as a key to histone deacetylase inhibition.

Authors:  Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-04-05       Impact factor: 8.250

7.  Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.

Authors:  Ivyna Pau Ni Bong; Ching Ching Ng; Shaik Kamal Fakiruddin; Moon Nian Lim; Zubaidah Zakaria
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

8.  Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Authors:  Christoph J Heuck; Jayesh Mehta; Tushar Bhagat; Krishna Gundabolu; Yiting Yu; Shahper Khan; Grigoris Chrysofakis; Carolina Schinke; Joseph Tariman; Eric Vickrey; Natalie Pulliam; Sangeeta Nischal; Li Zhou; Sanchari Bhattacharyya; Richard Meagher; Caroline Hu; Shahina Maqbool; Masako Suzuki; Samir Parekh; Frederic Reu; Ulrich Steidl; John Greally; Amit Verma; Seema B Singhal
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

9.  Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.

Authors:  Alfred Adomako; Veronica Calvo; Noa Biran; Keren Osman; Ajai Chari; James C Paton; Adrienne W Paton; Kateri Moore; Denis M Schewe; Julio A Aguirre-Ghiso
Journal:  BMC Cancer       Date:  2015-05-30       Impact factor: 4.430

10.  The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma.

Authors:  Huan Cheng; Zhonglei Deng; Zengjun Wang; Wei Zhang; Jiantang Su
Journal:  J Biomed Res       Date:  2011-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.